期刊文献+

慢性心力衰竭患者血清神经调节蛋白-1水平变化及意义 被引量:2

Changes and sinificance of serum neuregulin-1 levels in patients with chronic heart failure
原文传递
导出
摘要 目的探讨慢性心力衰竭(CHF)患者血清神经调节蛋白-1(NRG-1)水平的变化及意义。方法选取2017年10月至2018年6月郑州大学第一附属医院收治的CHF患者92例为CHF组,另选取同期年龄、性别相匹配的健康者45例为对照组。检测两组总胆固醇(TC)、低密度脂蛋白(LDL)、丙氨酸氨基转移酶(ALT)、肌酐及氨基末端B型利钠肽前体(NT-proBNP)水平,并以酶联免疫吸附法检测两组血清NRG-1水平;应用超声心动图测定左室射血分数(LVEF)及左室舒张末期内径(LVEDD)。结果两组年龄、性别、高血压及糖尿病患病率比较差异未见统计学意义(P>0.05)。CHF组肌酐、NT-proBNP、LVEDD、NRG-1水平为(82.16±22.83)μmol/L、(2834.97±2790.92)pg/ml、(56.83±11.77)mm、(1391.40±285.09)pg/ml,高于对照组的(69.87±15.92)μmol/L、(91.64±53.18)pg/ml、(44.80±3.62)mm、(1224.37±305.11)pg/ml,P<0.05;CHF组NT-proBNP、LVEDD随着LVEF降低而升高(P<0.05)。LVEF与LVEDD成强负相关关系(r=-0.868,P<0.05),与NT-proBNP成弱负相关关系(r=-0.350,P<0.05)。结论血清NRG-1可作为诊断CHF的参考指标,但用来判断CHF严重程度还需进一步探讨。 Objective To investigate the changes and sinificance of serum neuregulin-1(NRG-1)levels in patients with chronic heart failure(CHF).Methods Ninety-two patients with CHF admitted to the First Affiliated Hospital of Zhengzhou University from October 2017 to June 2018 were selected as CHF group,and 45 healthy people with similar age and gender ratios were selected as control group.Total cholesterol(TC),low density lipoprotein(LDL),alanine aminotransferase(ALT),creatinine and amino-terminal B-type natriuretic peptide(NT-roBNP)were measured in the two groups.The serum NRG-1 levels of the two groups were measured by enzyme-linked immunosorbent assay(ELISA).Left ventricular ejection fraction(LVEF)and left ventricular end diastolic diameter(LVEDD)were determined by echocardiography.Results There was no significant difference in age,gender or prevalence of hypertension and diabetes mellitus between the two group(P>0.05).The levels of creatinine,NT-proBNP,LVEDD,and NRG-1 in CHF group were(82.16±22.83)μmol/L,(2834.97±2790.92)pg/ml,(56.83±11.77)mm,(1391.40±285.09)pg/ml,respectively,higher than(69.87±15.92)μmol/L,(91.64±53.18)pg/ml,(44.80±3.62)mm and(1224.37±305.11)pg/ml in the control group(P<0.05).NT-proBNP and LVEDD in CHF group were significantly increased with decrease in LVEF(P<0.05).LVEF had a strong negative correlation with LVEDD(r=-0.868,P<0.05),and a weak negative correlation with NT-proBNP(r=-0.350,P<0.05).Conclusions Serum NRG-1 can be used as a reference marker for the diagnosis of CHF,but it is necessary to further investigate the role in diagnosing severity of CHF.
作者 吴晓丹 何飞 张金 徐智滔 刘泽华 Wu Xiaodan;He Fei;Zhang Jin;Xu Zhitao;Liu Zehua(Department of Cardiology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450052,China)
出处 《中国实用医刊》 2020年第7期6-9,共4页 Chinese Journal of Practical Medicine
基金 河南省科技攻关计划项目(182102310160) 河南省医学科技攻关计划省部共建备选项目(2018010001) 河南省高等学校重点科研项目计划(18A320050)。
关键词 心力衰竭 神经调节蛋白-1 射血分数 心室重构 Heart failure Neuregulin-1 Ejection fraction Ventricular remodeling
  • 相关文献

参考文献3

二级参考文献71

  • 1托伐普坦临床研究协作组,张健,朱文玲.常规治疗基础上联用托伐普坦片治疗心原性水肿的有效性和安全性的多中心随机、双盲、安慰剂对照研究[J].中华心力衰竭和心肌病杂志(中英文),2017,1(1):15-21. 被引量:26
  • 2Liu X,Gu X,Li Z,Li X,Li H,Chang J,et al.Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy.J Am Coll Cardiol 2006; 48:1438-1447.
  • 3Gao R,Zhang J,Cheng L,Wu X,Dong W,Yang X,et al.A phase Ⅱ,randomized,double-blind,multicenter,based on standard therapy,placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure.JAm Coll Cardiol 2010; 55:1907-1914.
  • 4Xu Y,Li X,Zhou M.Neuregulin-1/ErbB signaling:a druggable target for treating heart failure.Curr Opin Pharmacol 2009; 9:214-219.
  • 5Gassmann M,Casagranda F,Orioli D,Simon H,Lai C,Klein R,et al.Aberrant neural and cardiac development in mice lacking the ErbB4 neuregulin receptor.Nature 1995; 378:390-394.
  • 6Lee KF,Simon H,Chen H,Bates B,Hung MC,Hauser C.Requirement for neuregulin receptor erbB2 in neural and cardiac development.Nature 1995; 378:394-398.
  • 7Meyer D,Birchmeier C.Multiple essential functions of neuregulin in development.Nature 1995; 378:386-390.
  • 8Crone SA,Zhao YY,Fan L,Gu Y,Minamisawa S,Liu Y,et al.ErbB2 is essential in the prevention of dilated cardiomyopathy.Nat Med 2002; 8:459-465.
  • 9Jones LW,Haykowsky M,Peddle CJ,Joy AA,Pituskin EN,Tkachuk LM,et al.Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.Cancer Epidemiol Biomarkers Prev 2007; 16:1026-1031.
  • 10Lemmens K,Doggen K,De Keulenaer GW.Role of neuregulin-1/ErbB signaling in cardiovascular physiology and disease:implications for therapy of heart failure.Circulation 2007; 116:954-960.

共引文献5798

同被引文献20

二级引证文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部